JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

JNJ

234.09

+1.8%↑

ISRG

495

-0.8%↓

ABT

107.61

-1.84%↓

RDY

13.71

+4.74%↑

NEOG

10.62

+4.63%↑

Search

IQVIA Holdings Inc

Fechado

SetorSaúde

231.16 0.46

Visão Geral

Variação de preço das ações

24h

Atual

Mín

228.9

Máximo

231.72

Indicadores-chave

By Trading Economics

Rendimento

66M

332M

Vendas

83M

4.1B

P/E

Médio do Setor

32.889

90.422

Margem de lucro

8.098

Funcionários

91,000

EBITDA

102M

883M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+14.06% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de fev. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.3B

41B

Abertura anterior

230.7

Fecho anterior

231.16

Sentimento de Notícias

By Acuity

50%

50%

147 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

IQVIA Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de fev. de 2026, 23:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 de fev. de 2026, 23:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 de fev. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 de fev. de 2026, 23:38 UTC

Conversa de Mercado

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 de fev. de 2026, 23:28 UTC

Conversa de Mercado

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 de fev. de 2026, 23:23 UTC

Ganhos

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 de fev. de 2026, 22:57 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 22:22 UTC

Aquisições, Fusões, Aquisições de Empresas

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 de fev. de 2026, 22:08 UTC

Conversa de Mercado

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 de fev. de 2026, 21:51 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

2 de fev. de 2026, 21:49 UTC

Ganhos

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 de fev. de 2026, 21:39 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:36 UTC

Ganhos

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 de fev. de 2026, 21:34 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:28 UTC

Aquisições, Fusões, Aquisições de Empresas

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 de fev. de 2026, 21:23 UTC

Ganhos

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 de fev. de 2026, 21:19 UTC

Ganhos

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 de fev. de 2026, 21:17 UTC

Ganhos

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 de fev. de 2026, 21:17 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:10 UTC

Ganhos

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 de fev. de 2026, 21:08 UTC

Ganhos

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 de fev. de 2026, 21:07 UTC

Ganhos

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q Net $608.7M >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q Rev $1.41B >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 de fev. de 2026, 21:05 UTC

Ganhos

Palantir Technologies 4Q EPS 24c >PLTR

2 de fev. de 2026, 20:40 UTC

Conversa de Mercado

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparação entre Pares

Variação de preço

IQVIA Holdings Inc Previsão

Preço-alvo

By TipRanks

14.06% parte superior

Previsão para 12 meses

Média 262.5 USD  14.06%

Máximo 290 USD

Mínimo 230 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para IQVIA Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

150.68 / 153.45Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

147 / 352 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat